Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SPRO
stocks logo

SPRO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-0.200
-47.37%
0.00
-100%
-0.180
-28%
0.00
-100%
-0.170
+466.67%
Estimates Revision
The market is revising No Change the revenue expectations for Spero Therapeutics, Inc. (SPRO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.05%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+6.05%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Spero Therapeutics Inc (SPRO.O) is -3.21, compared to its 5-year average forward P/E of -2.58. For a more detailed relative valuation and DCF analysis to assess Spero Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.58
Current PE
-3.21
Overvalued PE
-0.76
Undervalued PE
-4.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.21
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.78
Undervalued EV/EBITDA
-3.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.21
Current PS
0.00
Overvalued PS
27.15
Undervalued PS
-2.74
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 486.02% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 486.02% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SPRO News & Events

Events Timeline

(ET)
2025-11-28
08:08:43
Spero Therapeutics Reveals Inducement Grant in Accordance with Nasdaq Listing Regulations
select
2025-10-21 (ET)
2025-10-21
05:46:08
Spero Therapeutics and GSK Reveal Efficacy and Safety Outcomes of PIVOT-PO Trial
select
2025-05-28 (ET)
2025-05-28
07:17:32
GSK reports PIVOT-PO study for tebipenem HBr stopped early for efficacy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-28Globenewswire
Spero Therapeutics Grants 90,000 RSUs to New Employee Under 2019 Inducement Plan
  • Employee Incentive Program: On November 3, 2025, Spero Therapeutics approved the grant of 90,000 restricted stock units (RSUs) to a new employee under its 2019 Inducement Equity Incentive Plan, aimed at attracting high-quality talent to support the company's R&D in rare diseases and multi-drug resistant bacterial infections.
  • Equity Incentive Structure: The RSUs will vest in four equal annual installments starting December 1, 2025, ensuring the new employee's continued employment, which enhances long-term commitment and stability, thereby promoting the company's growth in the competitive biopharmaceutical industry.
  • Compliance and Transparency: This grant complies with Nasdaq Listing Rule 5635(c)(4), indicating Spero's adherence to employee incentive regulations, which enhances investor confidence in corporate governance and improves the company's image in the capital markets.
  • Strategic Human Resource Investment: By implementing this incentive measure, Spero not only attracts and retains key talent but also enhances its innovation capacity and competitive edge in the rapidly evolving biopharmaceutical market, driving future growth for the company.
[object Object]
Preview
5.0
11-28Newsfilter
Spero Therapeutics Grants 90,000 RSUs to New Employee Under 2019 Inducement Plan
  • Employee Incentive Program: On November 3, 2025, Spero Therapeutics approved the grant of 90,000 restricted stock units (RSUs) to a new employee, aimed at attracting high-quality talent and enhancing the company's competitive edge.
  • Equity Incentive Structure: Under the 2019 Inducement Equity Incentive Plan, the RSUs will vest in four equal annual installments starting December 1, 2025, ensuring employee retention and stability as they must remain employed to receive the incentives.
  • Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring that the company adheres to relevant regulations while attracting new employees, thereby reducing legal risks.
  • Strategic Company Positioning: Spero focuses on developing innovative therapies for rare diseases and multi-drug resistant bacterial infections, and this equity incentive plan will help attract talent with relevant expertise, driving the company's long-term growth in the biopharmaceutical sector.
[object Object]
Preview
4.5
10-21NASDAQ.COM
Most Active Stocks in Pre-Market on October 21, 2025: BYND, GSIT, SPRO, TSLL, IONZ, SQQQ, NIO, F, SMR, IONQ, GM, LAC

  • NASDAQ 100 Pre-Market Indicator: The NASDAQ 100 Pre-Market Indicator is up 11.37 points to 25,152.39, with a total pre-market volume of 257,461,702 shares traded.

  • Most Active Stocks: Beyond Meat (BYND) leads with 135,675,012 shares traded, currently priced at $2.19, while other notable stocks include GSI Technology (GSIT) and Spero Therapeutics (SPRO).

  • Stock Performance Highlights: NIO Inc. (NIO) is trading at $6.98, slightly above its target price, while Ford Motor Company (F) is set to report earnings on October 23, 2025, with a forecasted EPS increase of 49%.

  • Market Trends: IonQ, Inc. (IONQ) and General Motors Company (GM) have shown significant price movements, with GM up 6.54 points to $64.54, reflecting strong market activity.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Spero Therapeutics Inc (SPRO) stock price today?

The current price of SPRO is 2.28 USD — it has increased 0 % in the last trading day.

arrow icon

What is Spero Therapeutics Inc (SPRO)'s business?

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

arrow icon

What is the price predicton of SPRO Stock?

Wall Street analysts forecast SPRO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Spero Therapeutics Inc (SPRO)'s revenue for the last quarter?

Spero Therapeutics Inc revenue for the last quarter amounts to 5.44M USD, decreased -59.60 % YoY.

arrow icon

What is Spero Therapeutics Inc (SPRO)'s earnings per share (EPS) for the last quarter?

Spero Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -59.38 % YoY.

arrow icon

What changes have occurred in the market's expectations for Spero Therapeutics Inc (SPRO)'s fundamentals?

The market is revising No Change the revenue expectations for Spero Therapeutics, Inc. (SPRO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.05%.
arrow icon

How many employees does Spero Therapeutics Inc (SPRO). have?

Spero Therapeutics Inc (SPRO) has 32 emplpoyees as of December 05 2025.

arrow icon

What is Spero Therapeutics Inc (SPRO) market cap?

Today SPRO has the market capitalization of 128.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free